WWOX (WW Domain Containing Oxidoreductase), also known as FOR or WOX1, encodes a tumor suppressor protein with two WW domains and a short-chain dehydrogenase/reductase (SDR) domain. Biallelic WWOX mutations cause autosomal recessive spinocerebellar ataxia type 12 (SCAR12), and the gene has been increasingly implicated in Alzheimer disease and Parkinson disease pathogenesis [@aqeilan2009].
The WWOX protein is unique among tumor suppressors in that it contains both protein-interaction WW domains and an enzymatically active SDR domain, giving it multiple mechanisms of action in cellular regulation [@iliopoulos2009].
The WWOX gene encodes a 414-amino acid protein that functions as a tumor suppressor and redox regulator. WWOX is highly expressed in the brain, particularly in the cerebellum, cortex, and hippocampus, where it plays critical roles in neuronal development, synaptic function, and response to oxidative stress.
Dysregulation or mutation of WWOX contributes to the pathogenesis of neurodegenerative disorders through multiple mechanisms, including impaired redox homeostasis, dysregulated apoptosis, and altered protein aggregation [@tumbazaritskaya2021].
| Attribute |
Value |
| Gene Symbol |
WWOX |
| Full Name |
WW Domain Containing Oxidoreductase |
| Chromosomal Location |
16q23.1 |
| NCBI Gene ID |
54345 |
| OMIM |
605515 |
| UniProt |
Q9H0M0 |
| Associated Diseases |
Alzheimer Disease, Spinocerebellar Ataxia, Parkinson Disease |
¶ Protein Structure and Function
WWOX is a 414-amino acid protein with two distinct functional domains:
- N-terminal WW domains (WW1, WW2): Two tandem WW domains that bind proline-rich motifs (PPxY) in target proteins
- C-terminal SDR domain: Short-chain dehydrogenase/reductase domain with oxidoreductase activity
The WW domains mediate protein-protein interactions with key regulatory proteins including p53, Apc, and transcription factors. The SDR domain catalyzes redox reactions, particularly involving quinones [@cheng2019].
- Brain: High expression in cerebellum, cortex, and hippocampus
- Peripheral tissues: Moderate expression in lung, breast, ovary
- Cellular localization: Cytoplasm, synaptic vesicles, mitochondria
- Tumor suppression: Induces apoptosis and inhibits cell proliferation
- Redox regulation: Controls cellular oxidative stress responses
- Neuronal survival: Protects against amyloid-beta and other neurotoxins
- Synaptic function: Involved in neurotransmitter release and vesicle trafficking
- Mitochondrial function: Maintains mitochondrial integrity
WWOX has emerged as an important player in Alzheimer disease pathogenesis. Postmortem studies show reduced WWOX expression in AD brains, and mouse models demonstrate that WWOX deficiency accelerates neuronal death in the presence of amyloid-beta pathology [@jung2015]. Proposed mechanisms include:
- Tau phosphorylation: WWOX modulates tau phosphorylation through regulation of kinases [@cheng2019]
- Amyloid-beta toxicity: WWOX protects against amyloid-beta induced neurotoxicity [@ouyang2018]
- Oxidative stress: Loss of WWOX impairs antioxidant responses
- Autophagy: WWOX deficiency leads to impaired autophagic clearance [@yang2022]
In Parkinson disease, WWOX may interact with alpha-synuclein and DJ-1 to modulate neuronal survival. The substantia nigra shows altered WWOX expression in PD models.
Biallelic loss-of-function mutations in WWOX cause autosomal recessive spinocerebellar ataxia type 12, characterized by:
- Early-onset cerebellar ataxia
- Developmental delay
- Seizures
- Progressive cerebellar atrophy [@mallaret2014]
flowchart TD
A["WWOX Protein"] --> B["Tumor Suppression"]
A --> C["Redox Regulation"]
A --> D["Neuronal Protection"]
B --> E["Apoptosis Induction"]
B --> F["Cell Cycle Arrest"]
C --> G["ROS Scavenging"]
C --> H["Quinone Metabolism"]
D --> I["Amyloid-beta Protection"]
D --> J["Tau Modulation"]
D --> K["Autophagy Regulation"]
I --> L["Neuronal Survival"]
J --> L
K --> L
style A fill:#e1f5fe,stroke:#333
style L fill:#c8e6c9,stroke:#333
- Expression: Reduced in AD brains [@fan2021]
- Mechanism: Impaired redox regulation, tau dysregulation
- Therapeutic target: WWOX-enhancing compounds under development
- Inheritance: Autosomal recessive
- Mutations: Loss-of-function variants
- Onset: Childhood
- Features: Ataxia, seizures, developmental delay [@mallaret2014]
- Interaction: May modulate alpha-synuclein toxicity
- Expression: Altered in substantia nigra
- WWOX-enhancing compounds: Being explored to upregulate WWOX expression
- SDR domain activators: Targeting the oxidoreductase domain
- AAV-WWOX: Being developed for SCAR12
- CRISPR approaches: Potential for correcting specific mutations
- Redox modulators: Enhance antioxidant function
- Autophagy inducers: Compensate for WWOX loss
- Neuroprotective agents: Downstream effectors
¶ Animal Models and Research
WWOX knockout mice recapitulate aspects of the human phenotype, including neurodegeneration and increased tumor risk. These models have been instrumental in understanding WWOX's role in neuronal survival [@sze2012].
- WWOX-knockout neurons: Show increased sensitivity to oxidative stress
- Amyloid-beta treated cells: WWOX provides protection
- ** Tau models**: WWOX modulates tau pathology
- Clinical testing: Available for SCAR12 diagnosis
- Carrier screening: For at-risk families
- Neurological evaluation: Recommended for WWOX variant carriers
- Multidisciplinary care: Involves geneticists, neurologists
- Mallaret M, et al. (2014). The tumor suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia
- Abbas A, et al. (2020). WWOX: molecular functions, clinical implications, and therapeutic targets
- Chen ST, et al. (2020). WWOX in neural development and neurological diseases
- Jung Y, et al. (2015). WWOX deficiency accelerates neuronal death in mouse models of Alzheimer disease
- Cheng Y, et al. (2019). WWOX modulates tau phosphorylation and aggregation
¶ Research Gaps and Future Directions
- WWOX expression modulators: Need for brain-penetrant small molecules
- Biomarkers: WWOX levels as disease progression markers
- Combination therapies: Targeting multiple pathways
- Gene therapy delivery: AAV variants for brain targeting